眼科市场展望：月报

Market Scope 出版眼科市场展望 (OMP) 已有 20 多年，提供有关眼科市场和专业的最新商业信息。今年的信息探索新技术和企业发展，并就行业面临的挑战发表看法。我们还分析和绘製季度行业数据以预测长期市场表现。

今年的信息提供了产品、事件和市场趋势的展望，以及及时的信息和分析，例如：

• 美国白内障、屈光矫正、青光眼和视网膜手术人数
• 新商业化的眼科设备/药品
• 正在调查的技术
• 影响眼科行业和医疗实践的经济问题
• 关于美国关于白内障、屈光矫正、视网膜、青光眼、干眼症设备和药物的监管信息
• AAO、ASCRS、ARVO 和 ESCRS 等主要眼科学会的演讲和趋势
• 未来眼科学会重要议程项目预览
• 眼科医疗趋势
• 眼科相关公司併购
• 新发布报告预览及总结
• 新的手术方法
• 影响眼科行业的争议
• 欧洲、日本、中国、印度等地区的眼科新闻
• 眼科市场竞争条件的变化
• 关于治疗视网膜、青光眼和干眼症的药物
• 包括新任命的执行官在内的高层人员概览
• 其他

Market Scope has published the Ophthalmic Market Perspectives (OMP) newsletter for more than 20 years. The newsletter provides the latest business information that is shaping ophthalmic markets and professions. Our articles explore new technologies and company developments. We offer opinions on issues facing the industry. We also analyze and chart quarterly industry data, and we forecast market performance over time.

The OMP provides perspective on products, events, and market trends, and timely information and analysis on the following:

• US cataract, refractive, glaucoma, and retinal procedure volumes

• Newly commercialized ophthalmic devices and pharmaceuticals

• Investigational technologies

• Economic issues affecting the ophthalmic industry and medical practice

• Yearly US regulatory updates on cataract, refractive, retinal, glaucoma, and dry eye devices and pharmaceuticals

• Presentations and developments at major ophthalmic meetings-the AAO, the ASCRS, ARVO, the ESCRS, and other key meetings

• Previews of significant agenda items at upcoming ophthalmic meetings

• Trends in the practice of ophthalmic medicine

• Mergers and acquisitions of ophthalmic companies

• Previews/summaries of newly published Market Scope comprehensive reports

• New surgical techniques

• Controversies affecting the ophthalmic industry

• Ophthalmic news from Europe, Japan, China, India, and other regions

• Shifts in the competitive landscape within ophthalmic market segments

• Retinal, glaucoma, and dry eye pharmaceuticals

• Briefs on new executive officers and other changes in top personnel

• And much more